- Women of reproductive potential must agree to consistently use adequate contraception / birth control between signing of the informed consent and 60 days after the last administration of the last study drug. The investigator or a designated associate should advise the subject how to achieve adequate contraception. Due to the lack of adequate reproductive toxicity data on anetumab ravtansine, subjects must concomitantly use 2 forms of adequate contraception.